Based on four independent clinical materials, reduced levels of nuclear-localized Stat5a were prognostic of unfavorable breast cancer outcome in patients who did not receive systemic adjuvant therapy and were associated with elevated risk of failure of antiestrogen therapy in patients. Here, STAT5A is linked to breast carcinoma.